Deleterious Interaction between the Neurosteroid (3α,5α)3-Hydroxypregnan-20-One (3α,5α-THP) and the Mu-Opioid System Activation during Forced Swim Stress in Rats
Biomolecules · 2023
DOI: 10.3390/biom13081205 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Giorgia Boero und 7 weiteren Autor:innen. Beteiligte Einrichtung: Bowles Center for Alcohol Studies, School of Medicine, University of North Carolina at Chapel Hill, 3027 Thurston Bowles Bldg., CB 7178, Chapel Hill,…. Hauptthemen laut MEDLINE: Analgesics, Opioid, Neurosteroids. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDA NIH HHS, NIAAA NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
The neurosteroid 3α,5α-THP is a potent GABAA receptor-positive modulator and its regulatory action on the HPA axis stress response has been reported in numerous preclinical and clinical studies. We previously demonstrated that 3α,5α-THP down-regulation of HPA axis activity during stress is sex-, brain region- and stressor-dependent. In this study, we observed a deleterious submersion behavior in response to 3α,5α-THP (15 mg/kg) during forced swim stress (FSS) that led us to investigate how 3α,5α-THP might affect behavioral coping strategies engaged in by the animal. Given the well-established involvement of the opioid system in HPA axis activation and its interaction with GABAergic neurosteroids, we explored the synergic effects of 3α,5α-THP/opiate system activation in this behavior. Serum β-endorphin (β-EP) was elevated by FSS and enhanced by 3α,5α-THP + FSS. Hypothalamic Mu-opiate receptors (MOP) were increased in female rats by 3α,5α-THP + FSS. Pretreatment with the MOP antagonist D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP; 2 mg/kg, IP) reversed submersion behavior in males. Moreover, in both males and females, CTAP pretreatment decreased immobility episodes while increasing immobility duration but did not alter swimming duration. This interaction between 3α,5α-THP and the opioid system in the context of FSS might be important in the development of treatment for neuropsychiatric disorders involving HPA axis activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bowles Center for Alcohol Studies, School of Medicine, University of North Carolina at Chapel Hill, 3027 Thurston Bowles Bldg., CB 7178, Chapel Hill, NC 27599, USA.
- Department of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
ORCID-Profile: Giorgia Boero, Todd K O'Buckley, Donita L Robinson
Förderung
- NIDA NIH HHS
- NIAAA NIH HHS
- National Institutes of Health
- Bowles Center for Alcohol Studies at the University of North Carolina at Chapel Hill
Zitieren
APA
Boero, G., McFarland, M. H., Tyler, R. E., O'Buckley, T. K., Chéry, S. L., Robinson, D. L., Besheer, J., & Morrow, A. L. (2023). Deleterious Interaction between the Neurosteroid (3α,5α)3-Hydroxypregnan-20-One (3α,5α-THP) and the Mu-Opioid System Activation during Forced Swim Stress in Rats. Biomolecules. https://doi.org/10.3390/biom13081205
Vancouver
Boero G, McFarland MH, Tyler RE, O'Buckley TK, Chéry SL, Robinson DL, et al. Deleterious Interaction between the Neurosteroid (3α,5α)3-Hydroxypregnan-20-One (3α,5α-THP) and the Mu-Opioid System Activation during Forced Swim Stress in Rats. Biomolecules. 2023. doi:10.3390/biom13081205
BibTeX
@article{Boero2023,
author = {Boero, Giorgia and McFarland, Minna H and Tyler, Ryan E and O'Buckley, Todd K and Chéry, Samantha L and Robinson, Donita L and Besheer, Joyce and Morrow, A Leslie},
title = {Deleterious Interaction between the Neurosteroid (3α,5α)3-Hydroxypregnan-20-One (3α,5α-THP) and the Mu-Opioid System Activation during Forced Swim Stress in Rats},
journal = {Biomolecules},
year = {2023},
doi = {10.3390/biom13081205}
}
EUVIMED